Weekly Investment Analysts’ Ratings Changes for Sarepta Therapeutics (SRPT)

Several analysts have recently updated their ratings and price targets for Sarepta Therapeutics (NASDAQ: SRPT):

• 3/7/2025 – Sarepta Therapeutics is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $105.00 price target on the stock.
• 2/27/2025 – Sarepta Therapeutics had its “sell” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 2/27/2025 – Sarepta Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $165.00 to $161.00. They now have an “outperform” rating on the stock.
• 2/27/2025 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
• 2/13/2025 – Sarepta Therapeutics had its “sell” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 2/11/2025 – Sarepta Therapeutics is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $136.00 price target on the stock.
• 1/30/2025 – Sarepta Therapeutics had its “sell” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 1/27/2025 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
• 1/15/2025 – Sarepta Therapeutics had its “sell” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 1/14/2025 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.

Sarepta Therapeutics Trading Up 1.0 %

SRPT traded up $1.00 during midday trading on Tuesday, hitting $100.69. The company’s stock had a trading volume of 490,207 shares, compared to its average volume of 913,000. Sarepta Therapeutics, Inc. has a 52-week low of $97.91 and a 52-week high of $173.25. The firm has a 50-day moving average price of $113.68 and a two-hundred day moving average price of $120.98. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $9.77 billion, a P/E ratio of 80.55 and a beta of 0.79.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. grew its position in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after acquiring an additional 88,474 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC grew its holdings in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Larson Financial Group LLC increased its stake in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after buying an additional 8,249 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Sarepta Therapeutics by 30.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock worth $9,772,000 after buying an additional 18,095 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.